Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

Creative Commons License

Mauguen A., Pignon J., Burdett S., Domerg C., Fisher D., Paulus R., ...More

LANCET ONCOLOGY, vol.14, pp.619-626, 2013 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 14
  • Publication Date: 2013
  • Doi Number: 10.1016/s1470-2045(13)70158-x
  • Journal Name: LANCET ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.619-626


Background The gold standard endpoint in clinical trials of chemotherapy and radiotherapy for lung cancer is overall survival. Although reliable and simple to measure, this endpoint takes years to observe. Surrogate endpoints that would enable earlier assessments of treatment effects would be useful. We assessed the correlations between potential surrogate endpoints and overall survival at individual and trial levels.